Table 1. Baseline characteristics of patients with Crohn’s disease (n=83).
WBC: white blood cell; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate
| Number (%) or means ± SD | |
| Demographics | |
| Age at diagnosis (years) | 28.5±12 |
| Female gender | 42 (50.6%) |
| Montreal Classification | |
| Age category A1: <17 A2: 17-40 A3: >40 | 26 (31.3%) 52 (62.7%) 5 (6%) |
| Disease location L1: Terminal Ileal L2: Colonic L3: Ileo-colonic | 29 (34.9%) 8 (9.6%) 46 (55.4%) |
| Disease behavior B1: Non-stricturing, non-penetrating B2: Stricturing B3: Penetrating | 40 (48.2%) 21 (25.3%) 22 (26.5%) |
| Endoscopic findings | |
| Deep ulceration at the terminal ileum Stenosis and stricture at terminal ileum Fistula opening at the terminal ileum | 43 (82.7%) 21 (40.4%) 13 (20.6%) |
| Laboratory findings | |
| WBCs (K/uL) | 8.9±3.3 |
| Hemoglobin (g/dL) | 11.5±2.4 |
| Platelets (K/uL) | 407±180.5 |
| Albumin (g/dL) | 27.7±8.6 |
| CRP (mg/L) | 33.9±35.5 |
| ESR (mm/H) | 26.7±19.2 |
| Medications | |
| Budesonide | 12 (14.6%) |
| Prednisolone | 47 (56.6%) |
| 5-Amino salicylic acid (5ASA) | 35 (42.2%) |
| Azathioprine (AZA) | 62 (74.7%) |
| Methotrexate (MTX) | 3 (3.8%) |
| Adalimumab | 36 (43.4%) |
| Infliximab | 15 (18.1%) |
| Complications | |
| Perforation | 44 (53%) |
| Intestinal obstruction | 38 (45.8%) |
| Abscess | 42 (50.6%) |
| Bowel resection | 52 (62.7%) |